ISRCTN95257778 https://doi.org/10.1186/ISRCTN95257778

UKALL R2 - Acute Lymphoblastic Leukaemia trial

Submission date 06/04/2000	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 06/04/2000	**Overall study status** Completed	
Last Edited 04/10/2007	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr PJ Darbyshire

Contact details
The Children's Hospital
Ladywood Middleway
Birmingham
United Kingdom
B16 8ET

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
G8223452

Study information

Scientific Title

Acronym
UKALL R2

Study objectives
To compare continuing chemotherapy with unrelated donor BMT in relapsed childhood ALL following a common re-induction and consolidation regimen.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Not Specified

Participant information sheet

Health condition(s) or problem(s) studied
Acute Lymphoblastic Leukaemia

Interventions
Continuing chemotherapy/unrelated donor BMT

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Survival, disease free survival

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/02/1995

Completion date
30/09/2008

Eligibility

Key inclusion criteria
They are children under 15 years at original diagnosis and treated on UKALL trials or pilot studies with first relapse less than 4 years from the start of treatment of ALL at any site and no suitable related bone marrow treatment (BMT) donor is available

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
200 - Closed to recruitment - in long term follow-up

Key exclusion criteria
1. They are multiply relapsed patients
2. They have a prior history of toxicity or organ damage such that completion of the protocol is felt unlikely at the outset
3. They have had an isolated CNS or testicular relapse more than 6 months off treatment.

Date of first enrolment
01/02/1995

Date of final enrolment
30/09/2008

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
The Children's Hospital
Birmingham
United Kingdom
B16 8ET

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
UK Medical Research Council

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/07/2005		Yes	No